Advanced irradiator tests GBM therapies

Despite continued efforts to develop new therapies, there is no cure for glioblastoma multiforme (GBM) brain tumours, with patients surviving a median of 15 months following diagnosis. Addressing this, researchers in the Netherlands have developed a strategy for more effective preclinical research. Combining in vitro drug screening with a spheroid tumour model and in vivo radiotherapy delivered by an advanced small-animal irradiator, the approach has been successfully implemented in an experimental study.